Search Results
Your search for ,pER matches 3965 pages
Showing 1701 - 1750Pediatric Cancer Investment Needs and Benefits: Findings From a Commission Created by The Lancet Oncology
Improving care for children with cancer worldwide could bring a triple return on investment and prevent millions of deaths, according to a new Commission report published by Atun et al in The Lancet Oncology. Without additional investment in childhood cancer care, new estimates produced for the...
Does Breastfeeding Affect Invasive Ovarian Cancer Risk?
In a large pooled analysis reported in JAMA Oncology by Babic et al, breastfeeding was associated with a significant reduction in risk for invasive ovarian cancers, including high-grade serous disease. Study Details The pooled analysis included data from 9,973 women with ovarian cancer and 13,843...
First-in-Human Study of Anteumab Ravtansine for Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Hassan et al found evidence of activity of the anti–mesothelin antibody-drug conjugate anetumab ravtansine in patients with advanced solid tumor types known to express the tumor-differentiation antigen mesothelin. The agent consists...
Harvard Medical Student’s Innovation: Disinfection You Can See
In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...
Cancer Care in the Time of COVID-19: Statement From Fox Chase Cancer Center
In an article published by Kutikov et al in Annals of Internal Medicine, practitioners from Fox Chase Cancer Center reviewed the challenges faced in cancer care during the COVID-19 crisis and suggested measures that may help to maintain standards of care while reducing risk of transmission as well...
Factors Associated With Small Adult Height in Childhood Cancer Survivors
In an analysis from the French Childhood Cancer Survivors (CCS) Study reported in the Journal of Clinical Oncology, Demoor-Goldschmidt et al found that receipt of pituitary irradiation, busulfan, and higher doses of lomustine were risk factors for small adult height in survivors of childhood...
Gynecologic Cancer Screening After a Natural Disaster
Cervical cancer screening rates were significantly affected in the years following the Great East Japan Earthquake of 2011, according to a report published by Miki et al in PLOS ONE. “Conflicts and disasters, and the social isolation that often follows, have a major impact on health care and lead...
Imaging-Based Radiotherapy Target Volume Reduction in Locally Advanced NSCLC
In a European trial (PET-Plan) reported in The Lancet Oncology, Nestle et al found that the use of reduced radiotherapy target volumes determined by 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) alone may achieve improved local control vs conventional target planning with...
Does Pembrolizumab Show Activity in Some Rare Cancers?
A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers. “Our findings that pembrolizumab has a favorable toxicity...
Evidence-Based Anticancer Drug Use in Physician Offices vs Hospital Outpatient Facilities
In a study reported in JCO Oncology Practice, Fishman et al found no significant difference in the use of optimal evidence-based anticancer drug regimens in physician offices vs hospital-based outpatient departments. However, the investigators found significantly higher costs of treatment in the...
FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC
On March 27, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). CASPIAN Trial Efficacy of this combination in patients...
AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
Phase II Trial Finds Neoadjuvant Immunotherapy Feasible in Oral Cavity Cancer
The results of a phase II study suggest that a short course of immunotherapy prior to surgery for oral cavity cancer may trigger tumor regression, possibly providing long-term benefits for patients. According to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium,1 a 3-week ...
How Exercise Oncology Can Improve Cancer Outcome and Survivorship
Researchers from the American College of Sports Medicine (ACSM) recently reviewed hundreds of epidemiologic studies on the link between physical activity and both cancer risk and cancer mortality. A subsequent analysis of the findings by a panel of experts representing 17 partner organizations,...
Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...
Expert Point of View: Christopher M. Booth, MD
Christopher M. Booth, MD, the invited discussant of the BEACON CRC quality-of-life findings, applauded the investigators for choosing overall survival and quality of life as endpoints in a trial that benefits a “vulnerable patient population with unmet needs.” Patients with BRAF-mutated metastatic...
TAPUR Basket Study: Biomarker-Driven Treatment Strategies Yield Benefits in Colorectal Cancer
Positive findings on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium, validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study.1-3 TAPUR, the first...
Digital Breast Tomosynthesis vs Digital Mammography Outcomes: Comparison Over 5 Years
A new study published by Conant et al in the journal Radiology found that the advantages of digital breast tomosynthesis over digital mammography, including increased cancer detection and fewer false-positive findings, are maintained over multiple years and rounds of screening. In addition,...
Addition of Vincristine/Irinotecan to Established Chemotherapy Regimen in Patients With Diffuse Anaplastic Wilms Tumor
In a Children’s Oncology Group study (AREN0321) reported in the Journal of Clinical Oncology, Daw et al found that the addition of vincristine/irinotecan to a regimen used in the National Wilms Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide plus...
COVID-19 Infection in Patients With Cancer in China
In a study of the COVID-19 crisis in China reported in The Lancet Oncology, Liang et al found that patients with cancer may be at a higher risk of COVID-19 respiratory disease requiring admission to hospital than individuals without cancer, and that those with cancer who contract the virus have a...
FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Colorectal Cancer Statistics 2020 Published
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...
Addition of Venetoclax to Cytarabine in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia. As noted by...
Annual Report to the Nation on the Status of Cancer Released
The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer. The annual report is a collaborative effort among the ...
Preoperative Letrozole for Postmenopausal Patients With Estrogen Receptor–Positive DCIS
In the phase II CALGB 40903/Alliance trial reported in the Journal of Clinical Oncology, E. Shelley Hwang MD, MPH, and colleagues found that preoperative letrozole was associated with beneficial imaging and biomarker changes in postmenopausal women with estrogen receptor (ER)-positive ductal...
Ho-166 Radioembolization After Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases
In a single-center Dutch phase II trial reported in The Lancet Oncology, Braat et al found that holmium Ho-166 radioembolization produced responses in patients with neuroendocrine tumor liver metastases who had received peptide receptor radionuclide therapy with lutetium Lu-177 dotatate. Study...
Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance
In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active...
Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendritic cell product given with sunitinib in 88 patients with metastatic renal cell carcinoma. The study ...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...
Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis
The investigational oral agent tucatinib added to trastuzumab/capecitabine reduced the risk of death by one-third and reduced the risk of disease progression or death by one-half in patients with heavily pretreated metastatic HER2-positive breast cancer, including those with untreated or previously ...
Participating in ‘Tremendous Progress’ in Hematologic Oncology, From Chernobyl to Stem Cell Transplantation
Richard E. Champlin, MD, Chairman of the nation’s largest Stem Cell Transplantation and Cellular Therapy program at The University of Texas MD Anderson Cancer Center, was born in Milwaukee and spent his formative years in Chicago. After high school, Dr. Champlin followed an early ambition in...
Concurrent Pembrolizumab and Chemoradiotherapy in Locally Advanced NSCLC
In a phase I trial reported in JAMA Oncology, Jabbour et al found that the use of pembrolizumab concurrently with chemoradiotherapy in advanced non–small cell lung cancer (NSCLC) was tolerable, and that progression-free survival with the combination therapy was 69.7% at 12 months. As stated by the...
Neoadjuvant and Adjuvant Pembrolizumab in Early Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, and colleagues, interim analyses of the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and use of adjuvant pembrolizumab vs placebo resulted in improvements in...
Plasma-Based Tumor Mutational Burden May Predict Response to Immunotherapy in Patients With Metastatic NSCLC
Patients with non–small cell lung cancer (NSCLC) with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to certain immunotherapy treatments than patients with a lower measure of mutations. A clinical trial showed that in cases where liquid...
Two Recent Studies Show Low-Nicotine Cigarettes Are Unlikely to Increase Compensatory Smoking
A pair of studies by Smith et al published in Cancer Epidemiology, Biomarkers & Prevention evaluating whether a mandated reduction in the nicotine content of cigarettes may cause smokers to compensate by engaging in compensatory smoking to obtain more nicotine has found that a reduction in...
Abbreviated Breast MRI vs Digital Breast Tomosynthesis Screening in Women With Dense Breasts
As reported in JAMA by Christiane K. Kuhl, MD, PhD, and colleagues, the ECOG-ACRIN EA1141 trial has shown that abbreviated breast magnetic resonance imaging (MRI) was associated with a significantly higher invasive breast cancer detection rate vs digital breast tomosynthesis among women with dense...
Three vs Six Months of Adjuvant Chemotherapy for High-Risk Stage II Colorectal Cancer
As reported in JAMA Oncology by Petrelli et al, noninferiority in relapse-free survival for 3 vs 6 months of adjuvant chemotherapy was not established among patients with resected high-risk stage II colorectal cancer in the Italian phase III TOSCA trial. A potential regimen effect was observed,...
Automated Referral Process for Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute, the use of a systemized, automated referral system that does ...
FDA Approves Neratinib/Capecitabine for Pretreated Patients With Metastatic HER2-Positive Breast Cancer
On February 25, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlynx), a tyrosine kinase inhibitor, in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the...
Physical Activity and Quality of Life in African American Cancer Survivors
New research suggests that regular exercise may improve the well-being of African American cancer survivors, but most survivors do not meet current recommendations for physical activity. The findings were published by Jennifer Beebe-Dimmer, MPH, PhD, and colleagues in the journal Cancer. Because...
The EHE Foundation Receives $450,000 Award From the Chan Zuckerberg Initiative
The EHE Foundation announced it will receive a $450,000 award from the Chan Zuckerberg Initiative (CZI) to drive progress toward treatments and a cure for epithelioid hemangioendothelioma (EHE), a rare vascular cancer diagnosed in about 20 individuals per year. The award recognizes The EHE...
Expert Point of View: Kevin Kalinsky, MD, MS
Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings of the analysis were in accordance with other studies in metastatic breast cancer, but they came...
Cancer in the Aging Population: ‘Leaving No One Behind’
With the motto of “leaving no one behind,” 420 delegates from 40 countries and 61 faculty members from 19 countries attended the Annual Meeting of the International Society of Geriatric Oncology (SIOG) in Geneva on November 14–16, 2019. SIOG serves as a platform to discuss a myriad of aspects...
Using Antioxidants and Other Supplements With Chemotherapy May Increase Risk of Breast Cancer Recurrence and Mortality
Using antioxidants and other dietary supplements before and during adjuvant chemotherapy for breast cancer may increase the risk of recurrence and “to a lesser extent, death,” according to an analysis of dietary and nutritional data from a phase III trial, published in the Journal of Clinical...
Patient-Reported Outcomes With Addition of Pembrolizumab vs Placebo to Pemetrexed/Platinum for Nonsquamous NSCLC
As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, global health status/quality of life was maintained or improved with the addition of pembrolizumab vs placebo to pemetrexed/platinum therapy for previously untreated metastatic nonsquamous non–small cell lung cancer...
Data From Colorectal Cancer Cohorts of TAPUR Study Presented
Positive findings from three Targeted Agent and Profiling Utilization Registry (TAPUR) study cohorts on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium.1-3 The TAPUR study is the first...
Expert Point of View: Christopher M. Booth, MD
Patients with BRAF-mutated metastatic colorectal cancer “pose clinical challenges for us every day,” said Christopher M. Booth, MD, Professor of Medical Oncology and the Canada Research Chair in Population Cancer Care at Queen’s University, Kingston, Ontario, the invited discussant of the...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Next-Generation BCMA-Targeted CAR T-Cell Therapies for Relapsed or Refractory Multiple Myeloma Explored in Early-Phase Trials
Two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses for patients with relapsed or refractory multiple myeloma, as well as potentially less cytokine-release syndrome and neurotoxicity compared with first-generation CAR T-cell products,...
